Details

Autor(en) / Beteiligte

• Nwachukwu, Chika
• Makhnoon, Sukh
• Person, Marieshia
• Muthukrishnan, Meera
• Kazmi, Syed
• Anderson, Larry D.
• Kaur, Gurbakhash
• Kapinos, Kandice A.
• Williams, Erin L.
• Fatunde, Oluwatomilade
• Sadeghi, Navid
• Robles, Fabian
• Basey, Alice
• Hulsey, Thomas
• Pruitt, Sandi L.
• Gerber, David E.

Titel

Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program

Ist Teil von

• Contemporary clinical trials communications, 2024-06, Vol.39, p.101292-101292, Article 101292

Ort / Verlag

Netherlands: Elsevier Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Involving diverse populations in early-phase (phase I and II) cancer clinical trials is critical to informed therapeutic development. However, given the growing costs and complexities of early-phase trials, trial activation and enrollment barriers may be greatest for these studies at healthcare facilities that provide care to the most diverse patient groups, including those in historically underserved communities (e.g., safety-net healthcare systems). To promote diverse and equitable access to early-phase cancer clinical trials, we are implementing a novel program for the transfer of care to enhance access to early-phase cancer clinical trials. We will then perform a mixed-methods study to determine perceptions and impact of the program. Specifically, we will screen, recruit, and enroll diverse patients from an urban, integrated safety-net healthcare system to open and active early-phase clinical trials being conducted in a university-based cancer center. To evaluate this novel program, we will: (1) determine program impact and efficiency; and (2) determine stakeholder experience with and perceptions of the program. To achieve these goals, we will conduct preliminary cost analyses of the program. We will also conduct surveys and interviews with patients and caregivers to elucidate program impact, challenges, and areas for improvement. We hypothesize that broadening access to early-phase cancer trials conducted at experienced centers may improve equity and diversity. In turn, such efforts may enhance the efficiency and generalizability of cancer clinical research.